Drug intelligence / Profile preview

HH30134

Development stage: Discontinued
Lead developer: Haihe
Modality: Small Molecules
Administration: Oral

Overview

HH30134 is an orally bioavailable small molecule inhibitor targeting multiple receptor tyrosine kinases, specifically AXL receptor (also known as UFO), FMS-like tyrosine kinase-3 (FLT3; CD135), and the neurotrophic tyrosine receptor kinases (NTRKs). It is being developed for its potential antineoplastic activity in advanced malignant solid tumors. The drug was jointly developed by Jinan University, Shanghai Haihe Biopharma, and the Shanghai Institute of Materia Medica at the Chinese Academy of Sciences. Clinical trials have been initiated to evaluate its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors[1][2][3][4].

Targets

AXL (AXL receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)Trk (Trk receptor family)

Beyond the preview

Go deeper on HH30134.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HH30134.

Explore the full profile